Due to the progressive nature of hereditary ATTR (hATTR) amyloidosis, managing the symptoms of the condition is an ongoing process. Physicians may prescribe medications to treat some of these symptoms and reduce the daily impact they may have.
Currently, there are no approved treatments for hATTR amyloidosis in the US, though some patients may benefit from a liver transplant, which could substantially reduce the amount of TTR protein made in the body.
Research is underway to evaluate potential treatment options for patients with hATTR amyloidosis, and there may be new options on the horizon for these patients. Investigational therapies that act at different points in the disease pathway to address the underlying cause of hATTR amyloidosis are in development.
Sekijima Y, J Neurol Neurosurg Psychiatry. 2015;86(9):1036-1043.
Ando Y, Orphanet J Rare Dis. 2013;8:31.